Teclistamab-Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma.

UNLABELLED: We report the case of a 76-year-old woman with refractory immune thrombocytopenia (ITP) and multiple myeloma (MM) who achieved remission of both conditions following teclistamab treatment. After failing multiple ITP therapies, her platelet count continued to decline. Initiation of teclistamab led to a rapid and sustained platelet increase, alongside MM response with measurable residual disease (MRD) negativity. Notably, remission was achieved after only four full doses, and the patient has remained in complete remission since. This case highlights teclistamab as a potential treatment for refractory ITP, suggesting a novel role for B-cell maturation antigen (BCMA)-targeted therapies in autoimmune diseases.

TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.